迪哲医药：多项血液瘤最新研究进展入选EHA年会

Core Insights - The company will present the latest clinical data from eight studies in its hematologic oncology pipeline at the upcoming 2025 European Hematology Association (EHA) annual meeting and the 18th International Conference on Malignant Lymphoma (ICML) [1] - The core product, Goresir (generic name: Golixanib capsules), and DZD8586 have made significant research progress in the lymphoma field, receiving three oral presentations since the American Society of Clinical Oncology (ASCO) annual meeting this year [1] - The latest two-year follow-up data from the Phase II prospective multicenter clinical study JACKPOT26, evaluating Goresir for maintenance therapy in peripheral T-cell lymphoma (PTCL) after first-line systemic treatment, has been selected for presentation at the EHA conference and will also be presented orally at the ICML conference [1] - Two studies of DZD8586 have been consecutively selected for presentation at top international academic conferences including ASCO, EHA, and ICML [1]